Myriad Genetics Management
Management criteria checks 1/4
Myriad Genetics' CEO is Sam Raha, appointed in Apr 2025, has a tenure of 1.33 years. total yearly compensation is $5.69M, comprised of 15.1% salary and 84.9% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth €452.19K. The average tenure of the management team and the board of directors is 1.3 years and 6.4 years respectively.
Key information
Sam Raha
Chief executive officer
US$5.7m
Total compensation
| CEO salary percentage | 15.07% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.3yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$113m |
| Mar 31 2026 | n/a | n/a | -US$400m |
| Dec 31 2025 | US$6m | US$857k | -US$366m |
| Sep 30 2025 | n/a | n/a | -US$400m |
| Jun 30 2025 | n/a | n/a | -US$395m |
| Mar 31 2025 | n/a | n/a | -US$101m |
| Dec 31 2024 | US$4m | US$750k | -US$127m |
| Sep 30 2024 | n/a | n/a | -US$116m |
| Jun 30 2024 | n/a | n/a | -US$155m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$5m | US$14k | -US$263m |
Compensation vs Market: Sam's total compensation ($USD5.69M) is above average for companies of similar size in the German market ($USD1.05M).
Compensation vs Earnings: Sam's compensation has increased whilst the company is unprofitable.
CEO
Sam Raha (53 yo)
Mr. Samraat S. Raha, also known as Sam, served as Chief Operating Officer at Myriad Genetics, Inc. since December 11, 2023 until April 30, 2025 and serves as its President, Chief Executive Officer and Dire...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$5.69m | 0.17% € 452.2k | |
| CFO & Principal Accounting Officer | 1yr | US$1.51m | 0.022% € 58.2k | |
| Chief Operating Officer | 1.3yrs | US$3.15m | 0.66% € 1.7m | |
| Chief Scientific Officer | 4.6yrs | US$1.86m | 0.34% € 891.4k | |
| Consultant | 1.3yrs | US$1.52m | 0.85% € 2.2m | |
| Chief Commercial Officer | 1.3yrs | US$6.00m | 0.062% € 161.3k | |
| Chief Technology Officer | less than a year | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Chief Legal Officer | 1.9yrs | no data | 0.027% € 71.2k | |
| Executive Vice President of Corporate & Business Development | less than a year | no data | no data | |
| Chief People Officer | 3.4yrs | no data | 0.036% € 95.2k | |
| Chief Medical Officer | 6.4yrs | no data | no data |
Experienced Management: MYD's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$5.69m | 0.17% € 452.2k | |
| Independent Director | 3.8yrs | US$334.25k | 0.10% € 266.2k | |
| Independent Director | 6.9yrs | US$343.00k | 0.14% € 361.0k | |
| Independent Director | 6.9yrs | US$338.50k | 0.097% € 252.2k | |
| Independent Director | 16.2yrs | US$338.50k | 0.18% € 468.4k | |
| Independent Director | 1.7yrs | US$211.93k | 0.049% € 128.3k | |
| Independent Chair of the Board | 16.9yrs | US$451.00k | 0.33% € 860.7k | |
| Independent Director | 5.9yrs | US$328.50k | 0.12% € 306.5k |
Experienced Board: MYD's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 02:43 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Myriad Genetics, Inc. is covered by 37 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |